{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:10:28Z","timestamp":1785190228413,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112462","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T13:46:43Z","timestamp":1719582403000},"page":"112462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative safety of monoclonal antibodies in chronic inflammatory airway diseases (chronic sinusitis with nasal polyposis and asthma): A network meta-analysis"],"prefix":"10.1016","volume":"138","author":[{"given":"Yang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suling","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"10.1016\/j.intimp.2024.112462_b0010","unstructured":"Global-Initiative-for-Asthma. Asthma Management and Prevention for Adults and children older than 5 years; 2019."},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0015","doi-asserted-by":"crossref","first-page":"e022644","DOI":"10.1136\/bmjopen-2018-022644","article-title":"Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care","volume":"9","author":"Vennik","year":"2019","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health."},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0025","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"Thelper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.intimp.2024.112462_b0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaip.2019.11.024","article-title":"Eosinophilic asthma","volume":"8","author":"Nelson","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.intimp.2024.112462_b0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2020.01.019","article-title":"Endotypes of chronic rhinosinusitis: Impact on management","volume":"145","author":"Cardell","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0050","doi-asserted-by":"crossref","first-page":"2102730","DOI":"10.1183\/13993003.02730-2021","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"59","author":"Reddel","year":"2021","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.intimp.2024.112462_b0055","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12931-019-1138-3","article-title":"Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis","volume":"20","author":"Edris","year":"2019","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.intimp.2024.112462_b0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"International mepolizumab study group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.intimp.2024.112462_b0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13223-019-0319-4","article-title":"Dermatomyositis associated with omalizumab therapy for severe asthma: a case report","volume":"15","author":"Jeimy","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.anai.2022.01.036","article-title":"Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Miss Ozuna","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.112462_b0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2024.112462_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2024.112462_b0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Int Med"},{"key":"10.1016\/j.intimp.2024.112462_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"10.1016\/j.intimp.2024.112462_b0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods."},{"key":"10.1016\/j.intimp.2024.112462_b0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity-subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.intimp.2024.112462_b0120","doi-asserted-by":"crossref","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G. Meta-analysis With R. New York, NY: Springer-Verlag; 2015.","DOI":"10.1007\/978-3-319-21416-0"},{"issue":"7","key":"10.1016\/j.intimp.2024.112462_b0125","doi-asserted-by":"crossref","first-page":"e010919","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open."},{"issue":"10","key":"10.1016\/j.intimp.2024.112462_b0130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2024.112462_b0135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med."},{"key":"10.1016\/j.intimp.2024.112462_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ."},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0145","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0150","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2024.112462_b0160","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"issue":"10209","key":"10.1016\/j.intimp.2024.112462_b0170","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2024.112462_b0185","doi-asserted-by":"crossref","unstructured":"Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials [published correction appears in J Allergy Clin Immunol. 2021 Jan;147(1):416]. J Allergy Clin Immunol. 2020;146(3):595-605. doi: 10.1016\/j.jaci.2020.05.032.","DOI":"10.1016\/j.jaci.2020.05.032"},{"issue":"6","key":"10.1016\/j.intimp.2024.112462_b0190","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.intimp.2024.112462_b0195","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0200","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.112462_b0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"A Phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"25","key":"10.1016\/j.intimp.2024.112462_b0215","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"10056","key":"10.1016\/j.intimp.2024.112462_b0220","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.intimp.2024.112462_b0225","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2024.112462_b0230","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.intimp.2024.112462_b0235","doi-asserted-by":"crossref","unstructured":"Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma [published correction appears in N Engl J Med. 2019 May 23;380(21):2082]. N Engl J Med. 2017;377(10):936-946. doi:10.1056\/NEJMoa1704064.","DOI":"10.1056\/NEJMoa1704064"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0240","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2024.112462_b0245","doi-asserted-by":"crossref","unstructured":"Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials [published correction appears in Lancet Respir Med. 2015 Apr;3(4):e15] [published correction appears in Lancet Respir Med. 2016 Oct;4(10):e50]. Lancet Respir Med. 2015;3(5):355-366. doi:10.1016\/S2213-2600(15)00042-9.","DOI":"10.1016\/S2213-2600(15)00042-9"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0250","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.intimp.2024.112462_b0255","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.112462_b0260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2024.112462_b0265","doi-asserted-by":"crossref","unstructured":"Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma [published correction appears in N Engl J Med. 2011 Feb 10;364(6):588]. N Engl J Med. 2009;360(10):973-984. doi:10.1056\/NEJMoa0808991.","DOI":"10.1056\/NEJMoa0808991"},{"issue":"13","key":"10.1016\/j.intimp.2024.112462_b0270","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0275","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.intimp.2024.112462_b0280","doi-asserted-by":"crossref","unstructured":"Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma [published correction appears in N Engl J Med. 2015 Apr 30;372(18):1777]. N Engl J Med 2014;371(13):1198-1207. doi:10.1056\/NEJMoa1403290.","DOI":"10.1056\/NEJMoa1403290"},{"issue":"9842","key":"10.1016\/j.intimp.2024.112462_b0285","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2024.112462_b0290","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax."},{"issue":"10","key":"10.1016\/j.intimp.2024.112462_b0295","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112462_b0300","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1016\/j.intimp.2024.112462_b0305","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112462_b0310","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112462_b0315","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med."},{"issue":"10039","key":"10.1016\/j.intimp.2024.112462_b0320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0325","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0330","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.intimp.2024.112462_b0335","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0340","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaip.2018.08.036","article-title":"Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.intimp.2024.112462_b0345","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","article-title":"Phenotypes and emerging endotypes of chronic rhinosinusitis","volume":"4","author":"Bachert","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112462_b0355","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell."},{"issue":"3","key":"10.1016\/j.intimp.2024.112462_b0360","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112462_b0365","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"issue":"13","key":"10.1016\/j.intimp.2024.112462_b0370","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"17","author":"Kim","year":"2017","journal-title":"Allergy Asthma Clin Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112462_b0375","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.112462_b0380","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/all.15205","article-title":"Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"77","author":"Boechat","year":"2022","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.intimp.2024.112462_b0385","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.intimp.2024.112462_b0390","doi-asserted-by":"crossref","first-page":"e12169","DOI":"10.1002\/clt2.12169","article-title":"Adverse events for biologics in patients with CRSwNP: a meta-analysis","volume":"12","author":"Shen","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.intimp.2024.112462_b0395","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042.","DOI":"10.1111\/all.14221"},{"key":"10.1016\/j.intimp.2024.112462_b0400","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/108854196778662255","article-title":"The clinical relationship of nasal polyps to asthma","volume":"17","author":"Larsen","year":"1996","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.intimp.2024.112462_b0405","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","article-title":"Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study","volume":"19","author":"Philpott","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.intimp.2024.112462_b0410","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.intimp.2024.112462_b0415","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J Asthma Allergy"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:20:31Z","timestamp":1722360031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":83,"alternative-id":["S1567576924009834"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112462","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of monoclonal antibodies in chronic inflammatory airway diseases (chronic sinusitis with nasal polyposis and asthma): A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112462"}}